All LegislationHouse Bill 3269HR 3269

ETHIC Act

Commerce

4 pages

house
senate
president

Introduced May 8, 2025 by Jodey Cook Arrington · Last progress May 8, 2025

House Votes

Pending Committee

May 8, 2025

Referred to the House Committee on the Judiciary.

Senate Votes

Vote Data Not Available

Presidential Signature

Signature Data Not Available

Recorded Votes

Recorded roll calls only

0 recorded

No recorded votes yet

Action History

IntroReferralMay 8, 2025
Referred to the House Committee on the Judiciary.
IntroReferralMay 8, 2025
Introduced in House

What do you think?

Sponsors (7)

AI Summary

Laws This Bill Would Affect

1 amendment

Amends35 U.S.C. 271(e)

Adds a new paragraph (7) to 35 U.S.C. 271(e) that limits the number of patents that may be asserted in an infringement action under that section against certain drug and biologic applicants, holders, and makers/importers to not more than one patent per defined 'Patent Group', prohibits bringing additional actions asserting patents in the same Patent Group against the same party, and defines 'Patent Group' based on commonly owned patents/applications related by disclaimers under section 253.

Text Versions

Introduced in House

May 8, 2025•4 pages

View PDF

Amendments

No Amendments

Limits the number of patents a plaintiff may assert in certain Hatch‑Waxman and biosimilar-related infringement suits to one patent per defined “Patent Group.” The rule applies to patent actions tied to abbreviated new drug applications (ANDA), certain 505(b)(2) applications, and biosimilar applications submitted on or after the law takes effect, and it bars later suits asserting other patents in the same Patent Group against the same party.